Trading of unit rights in Scandinavian ChemoTech's ongoing issue is extended

Report this content

Due to an incorrectly reported end date from Certified Adviser to Nasdaq, the trading of unit rights in Scandinavian ChemoTech's ongoing issue will be extended by one day compared to the date communicated in the prospectus. Thus, the last trading day for unit rights will be today, October 19, 2022.

For more information, please contact:

Mohan Frick, CEO


+46 (0)10-218 93 00


Certified Adviser: Erik Penser Bank, Tel:  Corporate Finance AB, Tel: +46 8-463 80 00, 



Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: